● Recruiting

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Condition: Diffuse Large B Cell Lymphoma · Sponsor: Ruijin Hospital

PhasePhase 2

Planned participants76

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

ZHAO weili · 64370045 · zwl_trial@163.com

XU pengpeng · 64370045 · pengpeng_xu@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05348213